Generic Name and Formulations:
Encorafenib 50mg, 75mg; caps.
Array BioPharma, Inc.
RECENT UPDATESMonograph added.
Indications for BRAFTOVI:
In combination with binimetinib, for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations Of use:
Not for treatment of wild-type BRAF melanoma.
Confirm BRAF V600E or V600K mutation prior to initiation. 450mg once daily with binimetinib until disease progression or unacceptable toxicity. Concomitant strong or moderate CYP3A4 inhibitors including grapefruit juice: avoid; if unavoidable, reduce Braftovi dose by ⅓ (if strong inhibitor) or by ½ (if moderate inhibitor). Dose modifications for adverse reactions: see full labeling. Refer to binimetinib labeling for dosing.
Monitor for new primary malignancies (cutaneous, non-cutaneous). Perform dermatologic exams prior to initiating, every 2 months during, and up to 6 months following treatment discontinuation. Discontinue if RAS-mutation (+) non-cutaneous malignancies develop. Uveitis: assess for visual symptoms at each visit; perform ophthalmologic exams regularly and for new or worsening visual disturbances. Long QT syndromes, significant bradyarrhythmias, severe or uncontrolled heart failure, concomitant drugs associated with QT prolongation; monitor. Correct hypokalemia and hypomagnesemia prior to and during treatment. Withhold, reduce or permanently discontinue dose if QTc >500ms. Increased risk of certain adverse reactions with Braftovi monotherapy; reduce dose if binimetinib interrupted or discontinued; see full labeling. Embryo-fetal toxicity. Pregnancy: exclude status prior to initiation. Females of reproductive potential should use effective contraception (non-hormonal methods) during and for 2 weeks after final dose. Nursing mothers: not recommended (during and for 2 weeks after final dose).
Potentiated by strong or moderate CYP3A4 inhibitors including grapefruit juice; avoid (see Adult). Antagonized by strong or moderate CYP3A4 inducers; avoid. May antagonize hormonal contraceptives; avoid. May affect sensitive CYP3A4 substrates. Avoid concomitant drugs known to prolong QT/QTc interval.
In combination with binimetinib: fatigue, nausea, vomiting, abdominal pain, arthralgia; hemorrhage.
Caps 50mg—60; 75mg—90
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Distinct Characteristics in Children at Risk for Schizophrenia vs Bipolar Disorder
- Nonstimulants May Be an Appropriate Alternative to Stimulants for Treating ADHD
- Psychotic Experiences Associated With Increased Risk for Eating Disorders in Adolescents
- Novel Parent-Child Interaction Therapy Targets Preschool-Aged Depression
- Remission of Treatment-Resistant Depression in Veterans Depends on Close Clinical Observation
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations
- From Abused Child to Serial Killer: Investigating Nature vs Nurture in Methods of Murder
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Therapy Focusing on Mindfulness, Interoception Improves Outcomes for Women With Substance Use Disorder
- Exposure to Antidepressants in Utero May Affect Childhood Motor Development
- Gender, MAOA Genotype, and History of Child Abuse Predict Tobacco and Cannabis Use
- Effect of Long-Term Lisdexamfetamine Dimesylate for Major Depressive Disorder
- 5-Factor Brief Negative Symptom Scale Validation in Schizophrenia